A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple Myeloma
Sponsored by CARsgen Therapeutics Co., Ltd.
About this trial
Last updated 2 years ago
Study ID
CT053-MM-05
Status
Not yet recruiting
Type
Observational
Placebo
No
Accepting
18+ Years
All Sexes
Trial Timing
Started 2 years ago
What is this trial about?
This study is a single-arm, open-label, multicenter, post-marketing, Phase IV, prospective, observational clinical trial to evaluate the efficacy and safety of the post-marketing product zevor-cel as treatment for subjects with R/R MM in the real world.
What are the participation requirements?
Inclusion Criteria
1. Age ≥ 18 years;
2. Subjects with refractory/relapsed multiple myeloma who meet product indication criteria and have received commercialized zevor-cel infusion.
3. Voluntary participation in this study and willingness to sign the informed consent form, for subjects incapable to provide consent, informed consent must be obtained from their legally acceptable guardians.
Exclusion Criteria
1. There were no specific exclusion criteria for this study。